Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by Ingiboyon Sep 07, 2023 1:05pm
141 Views
Post# 35624400

Buyout?

Buyout?Bluemoons20 your concern about a buyout are very valid concerns.  You posted:

"If there was a  'DEAL'  'TAKEOVER'  etc.  I  just wonder how that will come together and if the  'SMALL'
iinvestors  will be taken care of

Were about 17  million out when I  first got in.  Where are alll thse shares.  Would hate for the big guys to  take this 'Private'  at  10  cents  and then  make the deal  cutting  small guys out."

One thing that may prevent that and we can't forget are Mainpointe and Yofoto.  Here are their shares held and cost per share:

Yofoto: 5,357,900 @$.95 (approx.)
Mainpointe: 3,986,684 @ $.675

I don't think these two companies would be voting for any sort of buyout where they loose a majority of their investment in the company.





<< Previous
Bullboard Posts
Next >>